Articles tagged with Bone Marrow Transplantation
A new study has mapped the structure and function of healthy children's bone marrow cells, revealing age-dependent differences in blood cell formation. The atlas provides a valuable resource for researchers to better understand childhood leukemia and other blood disorders.
A multi-institutional effort aims to refine relapse prediction by identifying genetic markers in blood samples from patients with rare blood cancer. Analyzing blood samples from 190 patients, researchers found that tiny traces of persistent NPM1 mutation were linked to worse outcomes and lower survival rates.
A study of over 1,000 patients found that hematopoietic cell transplantation eliminated sickle cell disease symptoms in most patients, with a 90% seven-year survival rate. Late effects were mostly liver and lung issues, but the procedure's benefits outweighed risks for many patients.
Researchers have discovered that a chemotherapy drug can improve outcomes in stem cell transplants when donors and recipients are unrelated and have significant genetic differences. The study showed comparable survival rates and lower risks of complications among patients receiving transplants with more or less extensive genetic mismat...
A recent study found that blood cancer patients achieve good outcomes with a partial match drawn from the national public registry of donors when treated with cyclophosphamide. Survival rates at one year were comparable to those seen in other studies with fully matched donors.
A new app, BMT-CARE App, was tested in a randomized clinical trial to help caregivers manage stress and emotions related to bone marrow transplant patients. The app showed significant improvements in quality of life, burden, and mood symptoms compared to standard services.
A new partnership between Murdoch Children's Research Institute and Retro Biosciences will advance personalized therapies for children and adults with bone marrow failure, leukaemia, and other blood disorders. The $35M agreement aims to develop autologous therapies using the breakthrough blood stem cell discovery.
A new partnership between Murdoch Children's Research Institute and Retro Biosciences aims to develop personalized blood stem cell treatments for children and adults with blood disorders. The collaboration has the potential to prevent complications from mismatched donors by using a patient's own perfectly matched cells in transplants.
A new gene therapy has successfully restored immune function in nine children with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. The treatment has eliminated symptoms and reduced severe infections, offering a life-changing benefit to these patients.
A new machine learning model improves risk assessment for patients with myelofibrosis seeking a transplant, identifying high-risk patients with a 40% chance of dying within a year. The open-access model provides a practical tool for clinicians to enhance shared decision-making with their patients.
Researchers have developed a way to activate adult stem cells from human bone marrow, enabling their expansion outside the body for use in bone marrow regeneration. The new method significantly improves transplant success rates for patients with genetic disorders or those who require a bone marrow transplant.
An international team of scientists has molecularly decoded blood stem cell differentiation pathways using state-of-the-art sequencing methods. They identified a crucial surface protein, PD-L2, which suppresses the immune response by preventing T cell activation and release of inflammatory substances.
Researchers at UCSF have discovered that human lung tissue contains hematopoietic stem cells (HSCs) capable of producing red blood cells, platelets, and immune cells. The finding suggests the lungs could be a potent source for life-saving stem cell transplants, particularly for patients with leukemia.
A novel bone marrow transplant process has been shown to be safe and curative for adults with sickle cell disease, offering a viable alternative to recent gene therapy products. The treatment, which uses a 'half-matched' donor, results in high cure rates and low side effects, making it a more accessible option for patients.
A new case report reveals a rare and aggressive form of leukemia developing from donor cells nine years after a stem cell transplant. The disease, driven by genetic mutations in key genes, progresses despite intensive treatment and ultimately proves fatal.
Patients with lower education levels and income are less likely to receive stem cell transplants, but accessing treatment equalizes benefits. The study found socioeconomic factors have a less pronounced impact on post-transplant outcomes.
Researchers at Fred Hutchinson Cancer Center are addressing socioeconomic barriers to access to life-saving transplants for blood disorders. New leukemia treatment regimens have shown promise in clinical trials, while a prediction model highlights improved survivorship and quality of life outcomes for older patients after transplant.
Researchers tracked the long-term dynamics of transplanted stem cells in patients' bodies up to three decades post-transplant. They found that younger donors produce more vital stem cells, while older donors experience reduced immunity and higher relapse risk. The study provides new insights into donor selection and transplant success.
Researchers from USC and Caltech develop a new method to study hematopoietic stem and progenitor cells within the bone marrow without extracting them. This breakthrough could inform efforts to optimize bone marrow transplantation and provide insights into various health conditions, including cancer and heart disease.
A retrospective analysis of over 2,600 patients found that Black children were more likely to suffer severe graft-versus-host disease but overall survival rates improved across all racial groups. The study suggests that cord blood transplants are a vital lifeline for many patients and improve care for those without a matched donor.
A groundbreaking study published in Nature Medicine reports the first sustained remission of HIV infection following a bone marrow transplant in a patient without the CCR5-delta 32 mutation. Despite remaining susceptible to HIV, the virus remains undetectable nearly three years after antiretroviral treatment was stopped.
Researchers found that inflammation in the gut affects ISCs' regenerative capacity even after resolution of inflammation. The study used cellular and animal models to show that exposure to inflammation reprograms the epigenome, leading to reduced regeneration.
Melbourne researchers have developed a breakthrough in creating lab-grown human blood stem cells, which can be used to treat childhood blood disorders. The cells closely mimic those found in the human embryo and can create specific matched blood cells for transplantation, reducing complications and addressing donor shortages.
Researchers found that low-intensity blood stem cell transplants did not damage lungs and may help improve lung function in adults with sickle cell disease. Overall lung function remained stable or improved in patients after the procedure, according to a three-year study.
A new study found that heteroresistance, a phenomenon where a tiny fraction of bacteria remain resistant to antibiotics, is also present in fungal bloodstream infections in bone marrow transplant patients. The research identified the specific species of fungi responsible and developed a machine learning model to detect this type of inf...
A new combined cell therapy for kidney transplants uses a combination of bone marrow cells from the donor and Treg cells from the recipient to reduce the donor-specific reaction. This approach preserves the overall diversity of the T-cell receptor repertoire, crucial for immune defence.
The new treatment, nonmyeloablative haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy), has shown a two-year overall survival of 94.1% in children and adults, with no difference between age groups. The therapy is proving to be well-tolerated and offers an affordable alternative to expen...
Researchers discovered that children with the worst outcomes had significantly fewer microbial species overall, but marked populations of Staphylococcus bacteria and viruses. The study used metagenomic next-generation sequencing to analyze lung fluid samples from 229 pediatric patients, revealing links between microbiome composition an...
Researchers discuss the benefits of CAR-T therapy in treating B-cell lineage acute lymphoblastic leukemia (B-ALL) in children. The therapy, tisagenlecleucel, has shown promising results and is now priced at $508,250, a more manageable cost compared to other gene therapies.
A new study found that bone marrow transplants from half-identical relatives offer significantly better outcomes for Hispanic patients with acute lymphoblastic leukemia (ALL), who face challenges in finding fully matched donors. The transplants resulted in a 70% lower risk of relapse compared to those from fully matched donors.
A new study published in JAMA Oncology highlights the importance of testing for measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. The researchers found that detecting MRD can help predict cancer recurrence and improve patient outcomes.
Survival after hematopoietic cell transplant improved over time for all racial/ethnic groups, with non-Hispanic African Americans still experiencing worse outcomes. Hispanic patients now have similar survival rates to non-Hispanic whites.
Researchers successfully transmitted familial Alzheimer's disease to normal lab mice through bone marrow stem cell transplant. The recipients developed cognitive decline and amyloid buildup at an accelerated rate, highlighting the systemic nature of Alzheimer's disease.
Researchers identified a case of chronic inflammatory bowel disease after a blood stem cell transplant, linked to a genetic mutation in the recipient's body. Genetic analysis revealed that the donor carried a similar mutation, which triggered an autoimmune response.
A novel risk score predicts cardiovascular complications after bone marrow transplant with high accuracy, helping guide patient selection and post-transplant management. Patients with preexisting cardiovascular conditions are more likely to experience long-term complications.
Researchers found that ASCOT reverses some age-related protein expression changes, enriching processes related to the complement cascade and immune system in patients with poor ovarian response. In contrast, patients with premature ovarian insufficiency showed enrichment in responses to oxygen-containing compounds and growth hormones.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
A study suggests that Brazil's unique genetic diversity could provide the necessary number of stem cell lines to cover 95% of the world's population. Researchers estimate that at least 559 distinct cell lines would be required for this goal, and Brazil could contribute considerably to a global iPS cell bank.
A small molecule drug improved the fitness of hematopoietic stem cells used in cell transplants, potentially enhancing the success of procedures like ex vivo gene therapy. The study found that targeting extracellular vesicles relieved stress on cells outside the body, improving their performance when transplanted back in.
Dr. Hung Nguyen is studying how medium chain fatty acid foods like coconut oil and avocados affect GVHD severity and mortality in transplant patients. His goal is to develop a dietary approach that reduces inflammation and corticosteroid use, improving patient outcomes for blood cancers.
Researchers have made a significant discovery in gene therapy, showing that genetically engineered blood stem cells can be created while still in the bone marrow. This approach eliminates the need for chemotherapy and transplantation of corrected cells, cutting costs and improving access to critical treatments.
A study from the University of Gothenburg found that even vulnerable people with compromised immune systems achieved good antibody levels after three doses of COVID-19 mRNA vaccine. This is particularly significant for those at risk of severe Covid-19, as they showed catch-up antibody responses and high levels of hybrid immunity.
A Swiss patient has achieved 20 months of HIV remission after a bone marrow transplant performed as part of cancer treatment. The patient's cells remained HIV-permissive despite the absence of a protective mutation, yet the virus was still undetectable after antiretroviral therapy was discontinued.
Researchers have developed an experimental antibody treatment that largely prevented graft versus host disease in the intestines, without causing broad immune suppression. The treatment blocked donor T-cell attack and increased survival rates in preclinical models.
Researchers have developed a new standard for preventing graft-versus-host disease (GVHD) after stem cell transplant, showing improved efficacy and reduced side effects compared to the current gold standard. The new regimen achieved higher rates of patient survival without GVHD complications, making it a more effective option for patie...
A new study shows that newborn screening for severe combined immunodeficiency disease (SCID) has significantly increased the survival rate of children after bone marrow transplantation from 73% to 87%. Children diagnosed at birth have a 92.5% survival rate without infection, while those diagnosed later have lower rates.
Widespread newborn screening for severe combined immunodeficiency (SCID) has increased the five-year survival rate from 73% to 87%, with 92.5% of children surviving five years or more after treatment. The study, led by NIAID, demonstrates that early identification and prompt treatment have saved countless lives.
Researchers at UCL have developed base-edited T-cells that can fight leukemia, showing promise in a NHS clinical trial. Three patients with relapsed T-cell leukaemia were treated with the cells, with one patient experiencing complete remission after just four weeks.
Researchers from Oregon Health & Science University have discovered how stem cell transplantation can kill the virus that causes AIDS. The study, published in the journal Immunity, reveals that two circumstances must co-exist for a cure to occur and documents the order in which HIV is cleared from the body.
A team from the University of Tsukuba has discovered that the enzyme ELOVL6 plays a significant role in the development of acute myeloid leukemia, a type of blood cancer. The study found that high levels of ELOVL6 are linked to shorter survival rates for leukemia patients.
A large, prospective study led by the Fred Hutchinson Cancer Center recommends that cancer patients receive SARS-CoV-2 mRNA vaccination three to four months after bone marrow transplant. The study found that early vaccination can provide crucial protection against severe COVID-19 in this vulnerable population.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
Researchers at the University of Wisconsin-Madison have identified a specific cell population, called CD4/CD8 double positive T cells, that causes graft-versus-host disease in bone marrow transplants. The team's findings may lead to targeted treatments and improved patient outcomes.
Researchers developed a blood test to detect residual leukemia in AML patients before bone marrow transplant, showing that those with persistent mutations had higher risks of relapse and lower survival rates. The study supports ongoing research on precision medicine and personalized post-transplant care.
Researchers discovered that bone marrow transplants can halt the development and progression of brain blood vessel disease in adults with sickle cell disease. The study found that receiving stem cell transplants led to positive changes in blood vessels, reducing the risk of stroke among patients with the condition.
A new Pitt study reframes understanding of graft-versus-host disease, suggesting that GVHD is locally maintained by donor T cells in target tissues. The research, published in Immunity, offers an alternative model that could guide development of novel therapies and improve outcomes for stem cell recipients.
Researchers at Children's Hospital of Philadelphia have developed a custom-built application to automate the determination of engraftment after hematopoietic stem cell transplant. The tool has been shown to improve accuracy of reported engraftments, reducing errors in neutrophil and platelet engraftment reporting.
A new gene therapy treatment has shown promising results in a clinical trial for Artemis-SCID patients, improving their immune function and reducing treatment complications. The treatment involves adding a healthy copy of the Artemis gene to the patient's own cells, resulting in improved T-cell and B-cell immunity.
Researchers at UVA Cancer Center have identified interleukin-1 as a crucial contributor to the development of myelofibrosis, a potentially deadly bone marrow cancer. Targeting this cytokine could prevent myelofibrosis from progressing and spare bone marrow scarring.
A KAUST-led research team identified two drug treatments that boost the activity of molecules involved in cell adhesion, enhancing the ability of blood-forming stem cells to enter the bloodstream and produce new blood. This breakthrough could lead to improved bone marrow transplant success for leukemia patients.